ClinicalTrials.gg
TerminatedNCT05906732Updated Jul 24, 2025Results posted

Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).

A Phase 1/2 interventional study of LQT-1213 and Placebo in Long QT Syndrome, sponsored by Thryv Therapeutics, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Thryv Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Advancing an alternative SGK1 inhibitor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Long QT Syndrome with a site in United States — 7 open to participants now, 7 under way, 1 of them phase 3. Long QT Syndrome · United States.

Enrollment
15th of 28
42 · median 44
Started
2023
with 2 others
Phase 1/2
Only one
of the 44
Registered
41st of 44
by date
Lead sponsor
3 of 44
Thryv Therapeutics, Inc.

Among the 44 studies in Long QT Syndrome with a site in United States, this one is the 15th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 1/2, and was the 41st registered.

Long QT Syndrome

101 studies on the registry are indexed under Long QT Syndrome; 20 are open to participants now.

Browse Long QT Syndrome studies →

Open to participants now

7 of the 44 studies in Long QT Syndrome with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Long QT Syndrome studies recruiting now, 10 (71%) set no upper age limit and 3 (21%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Long QT Syndrome with a site in United States, or all of them as a file.
02

Study summary

Part 1: This is a Phase 1b, randomized, double-blind, crossover, dose escalation, placebo-controlled study to evaluate the effect of oral LQT-1213 on dofetilide-induced QTc prolongation in healthy adult subjects. This is a 2-treatment, 2-period crossover study with approximately up to 28 healthy subjects, with screening procedures within 28 days of enrolment.

Part 2: This is a Phase 2a, single-blind, placebo run-in, multiple-dose safety study to evaluate the safety, tolerability, and PK of LQT-1213 in patients diagnosed with LQT2 or LQT3. Up to 12 participants with LQT2 and up to 12 participants with LQT3 will be recruited.

Read the detailed description

Part 1: This is a 2-treatment, 2-period crossover study. Approximately 28 healthy subjects, with the attempt to balance for sexes, will be enrolled to complete approximately up to 20 subjects in the study. In both treatment periods, all subjects will receive dofetilide on Days 1 and 2 of each period. Randomization will take place before Day 3 of Period 1. Subjects will be randomly assigned to 1 of 2 treatment sequences (AB or BA).

Part 2: Up to 12 participants with LQT2 and up to 12 participants with LQT3 will be enrolled. After initial screening, which may be conducted remotely by the CRU, individual participants with LQT2 or LQT3 will undergo a 1-day, single-blind placebo run-in period followed by 3 dosing days of LQT-1213 administered TID (the last dosing day will have a single dose). Participants will be discharged from the CRU on Day 5. Approximately 7 days after discharge from the CRU, the Follow-up Visit will be conducted remotely via telephone call.

03

Conditions studied

  • Long QT Syndrome

Browse trials for

Keywords

  • LQT-1213
  • Congenital Long QT Syndrome
  • LQTS
  • Serum glucocorticoid regulated kinase-1
  • SGK-1 inhibitor
  • Drug induced long QT
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part1:

  1. Male and female subjects between 18 and 60 years of age (inclusive) at Screening.
  2. Not previously enrolled in a clinical study with LQT-1213.
  3. Normal general health.
  4. within 18.0 to 32.0 kg/m2, inclusively at Screening.
  5. Female subjects of nonchildbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before Screening) or , defined as spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone in the postmenopausal range at Screening, based on the central laboratory's ranges.
  6. Female subjects of (ie, ovulating, premenopausal, and not surgically sterile) must use a highly effective regimen during their participation in the study and for 30 days after the last administration of study drug. Highly effective contraceptive methods are defined as those with \<1% failure rate per year. Acceptable methods of contraception for female subjects enrolled in the study include the following:

    • Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable
    • Intrauterine device
    • Intrauterine hormone-releasing system
    • Bilateral tubal occlusion
    • Vasectomized partner
    • Heterosexual abstinence
  7. Male subjects and their partners must use highly effective methods of contraception (ie, condom and spermicide) for the entire duration of the study. Male subjects must continue to use contraception and refrain from fathering a child and sperm donation for 90 days after the last administration of study drug. Acceptable methods of contraception for male subjects enrolled in the study include the following:

    • Condoms and spermicide
    • Surgical sterilization (vasectomy) of the subject at least 26 weeks before Screening
    • Heterosexual abstinence (subject must agree to use condom and spermicide if they become sexually active)
  8. Understand the requirements of the study and voluntarily consent to participate in the study.

Part 2:

  1. Male and female participants 18 years of age or older at Screening.
  2. Body weight of at least 45 kg at Screening.
  3. Female participants of nonchildbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before Screening) or postmenopausal, defined as spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone in the postmenopausal range (>40 mlU/mL) at Screening, based on the central laboratory's ranges.
  4. Female participants of childbearing potential (ie, ovulating, premenopausal, and not surgically sterile) must use a highly effective contraceptive regimen during their participation in the study and for 30 days after the last administration of study drug. Highly effective contraceptive methods are defined as those with \<1% failure rate per year. Acceptable methods of contraception for female participants enrolled in the study include the following:

    • Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable
    • Intrauterine device
    • Intrauterine hormone-releasing system
    • Bilateral tubal occlusion
    • Vasectomized partner
    • Heterosexual abstinence
  5. Male participants and their partners must use highly effective methods of contraception (ie, condom and spermicide) for the entire duration of the study. Male participants must continue to use contraception and refrain from fathering a child and sperm donation for 90 days after the last administration of study drug. Acceptable methods of contraception for male participants enrolled in the study include the following:

    • Condoms and spermicide
    • Surgical sterilization (vasectomy) of the participant at least 26 weeks before Screening
    • Heterosexual abstinence (participant must agree to use condom and spermicide if they become sexually active)
  6. LQT2 or LQT3 mutation:

    • LQTS 2: Participants with potassium voltage-gated channel subfamily H member 2 (KCNH2) mutations that are dominant negative and considered to be pathologic or likely pathologic by the screening laboratory can be included after approval from the sponsor. Participants with haploinsufficiency will not be eligible for this study.
    • LQTS 3: Participants with a sodium voltage-gated channel alpha subunit 5 (SCN5A) gene chromosome 3 mutations that are mutations and considered to be pathologic or likely pathologic by the screening laboratory can be included after approval from the sponsor. Participants with mutations not associated with Brugada syndrome or overlap syndromes or where mutations affect the window current or the persistent 'late' Na current to exert a primary or major role in the phenotype, will be eligible for this study.
  7. interval ≥480 and ≤560 ms determined at Screening and on Day -1 triplicate ECGs as assessed by a physician trained in complex interpretation.
  8. The first 2 participants with LQT2 require having an ICD before further participants with LQT2 are enrolled and the first 2 participants with LQT3 require having an ICD before further participants with LQT3 are enrolled. This stipulation may be altered based on agreement between the principal investigator and Sponsor based on emerging data. The ICD implantation must have been at least 2 months before Screening.

    Note: Subsequent participants may or may not have had an ICD. The results of the ICD interrogation within the last 6 months should be available for review unless waived by the investigator and sponsor.

  9. Understand the requirements of the study and voluntarily consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

Part 1:

  1. On Day 1 at 3 hours postdose in Period 1 only, of the first cycle of dofetilide, the on the triplicate ECGs will be manually confirmed by cardiologist experienced in interval measurements. The ECG measurements at baseline and at the 3-hour time points will be performed by the same technician and cardiologist. If the mean QTcF increase from baseline is \<25 ms on triplicate safety ECGs compared to the mean from baseline (all ECG QTcF measurements averaged), the subject will be disqualified from further study participation.
  2. gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition, which, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results. No history of myocardial infarction or angina or ischemic heart disease, nonsustained or sustained ventricular tachycardia, atrial fibrillation, stroke, , syncope, congestive heart failure, family history of LQTS, Torsades de Pointes, or sudden cardiac death.
  3. Female subjects must not be pregnant, lactating, or breastfeeding, and must not be planning to become pregnant.
  4. Female subjects of must have a negative result for the serum pregnancy test at Screening and Check-in.
  5. Clinically significant abnormal findings on the physical examination or medical history during Screening as deemed by the investigator.
  6. Participated in a previous clinical study in the previous 3 months before dosing.
  7. Donation of blood volume greater than 300 mL within 30 days before Screening and agree to avoid donation from Screening and throughout the study.
  8. At Screening and on Day -2, if the 12-lead ECG demonstrates any of the following: PR >240 ms; QRS >110 ms, or QTcF \<400 ms and >440 ms; second- or third-degree atrioventricular block; bundle branch block, significant ST-T wave abnormalities or flat T waves that could interfere with QT analysis. If HR \<50 or >85 bpm, then 2 more ECGs will be recorded, and the mean values will be used.
  9. Known sensitivity to kinase inhibitors.
  10. Abnormal renal function with an estimated (eGFR) of \<70 mL/min/1.73 m2, with eGFR calculated by the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula at Screening. One retest of the exclusionary eGFR value is allowed at the discretion of the investigator.
  11. Subject has abnormal liver function tests (transaminases or total ) greater than 2.5 × the at Screening or baseline. One retest of exclusionary abnormal liver function tests is allowed at the discretion of the investigator.
  12. Subject has a positive serology test for antibodies, surface antigen, or virus antibody at Screening.
  13. Subject has a \<11.0 g/dL, potassium \<3.8 mg/dL, magnesium \<1.9 mg/dL, or calcium \<8.5 mg/dL at Screening or baseline. One retest of exclusionary hemoglobin, potassium, magnesium, and calcium is allowed at the discretion of the investigator. Electrolyte supplementation is allowed at any time as long as it is >4 hours before dosing.
  14. Subject has a history of to drugs with a clinically significant reaction or any clinically significant hypersensitivities.
  15. Subject has an allergy to band aids, adhesive dressing, or medical tape.
  16. Subject has a history within the past 2 months of strenuous exercise (eg, marathon running) and is unwilling to refrain from strenuous exercise from 7 days before Check-in and until the end of the study. Subject has abnormal creatine phosphokinase test greater than 3 × the upper limit of normal at Screening and baseline. One retest of exclusionary abnormal creatine phosphokinase tests is allowed at the discretion of the investigator.
  17. Subject is unable to refrain from or anticipates the use of any drug, including prescription and nonprescription medications (with the exception of hormonal ), herbal preparations, or vitamin supplements beginning 14 days before the first dose and until the end of the study. After dosing, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the investigator or designee.

    1. Hepatic or renal clearance altering agents within 30 days before the first dose and until the end of the study.
    2. Avoid vaccinations from Screening until the end of the study.
    3. Has consumed cruciferous vegetables (eg, kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, and mustard greens) or charbroiled meats within 7 days before Check-in through the Follow-up Visit.
    4. Use of any drugs known to be significant strong inducers of cytochrome P450 (CYP) 3A enzymes, including St. John's Wort, for 28 days before Day -1 or 5 half-lives (whichever is longer) and through the Follow-up Visit.
    5. Has consumed Seville oranges, grapefruit and/or grapefruit juice within 14 days before Check-in and is unwilling to abstain from consuming these items until the end of the study.
  18. Subject is considering or scheduled to undergo any surgical procedure during the study.
  19. Subject has experienced an acute illness that has resolved in less than 14 days before the first study drug dose or has had a major illness or hospitalization within 1 month before the first study drug dose.
  20. Subject is unwilling to abstain from ingestion of caffeine- or xanthine-containing products (eg, tea, coffee, chocolate, cola, etc.) beginning 96 hours before Check-in until the final PK sample of the study has been collected.
  21. Subject is unwilling to abstain from alcohol beginning 48 hours before Check-in and until the final PK sample of the study has been collected.
  22. Subject has a history of high alcohol consumption within 9 months before Screening, defined as an average weekly intake of >14 units for males or >10 units for females.

    One unit is equivalent to 8 g of alcohol: a half-pint (\~240 mL) of beer, 1 glass (125 mL) of wine, or 1 measure (25 mL) of spirits.

  23. Subject has a history of drug abuse in the 3 years before Screening or positive screen for drugs of abuse or alcohol at Screening or baseline. Subjects may undergo a repeat urine drug screen at the discretion of the investigator.
  24. Subject uses or has used tobacco-or nicotine-containing products (eg, cigarettes, cigars, chewing tobacco, snuff, etc.) within 6 months before Screening and is unwilling to abstain from tobacco-containing products until the end of the study, based on subject self-reporting.
  25. Subject, who, for any reason, is deemed by the investigator to be inappropriate for this study or has any condition which would confound or interfere with the evaluation of the safety, tolerability, or PK of the drug or prevent compliance with the study protocol.

Part 2:

  1. Clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or significant structural cardiovascular disease or any other condition beyond LQT2 or LQT3, which, in the opinion of the investigator or sponsor, would jeopardize the safety of the participant or impact the validity of the study results. History of myocardial infarction or ongoing angina or active ischemic heart disease, atrial fibrillation, stroke, or transient ischemic attack within the past 12 months, greater than Class II congestive heart failure, bundle branch block, hemodynamically significant ventricular tachycardia not due to Torsades de Pointes, or Brugada syndrome.
  2. Participant has a history of an aborted cardiac arrest, ICD implantation, syncopal episode due to a ventricular arrhythmia or where confidence in the etiology cannot be established, or appropriate ICD therapy for ventricular tachycardia/ventricular fibrillation within 2 months before Screening. Participants with LQT2 or LQT3 can be enrolled after the 2-month time period has lapsed.
  3. Female participants must not be pregnant, lactating, or breastfeeding, and must not be planning to become pregnant.
  4. Female participants of childbearing potential must have a negative result for the serum pregnancy test at Screening and Check-in.
  5. Clinically significant abnormal findings on the physical examination at Check-in or medical history during Screening as deemed by the principal investigator.
  6. Currently participating in another interventional clinical study.
  7. Donation of blood volume greater than 300 mL within 30 days before dosing and unwilling to avoid donation from Screening and throughout the study.
  8. Screening diastolic blood pressure \<45 or >95 mm Hg, systolic blood pressure \<90 or >150 mm Hg, or with sponsor and investigator approval.
  9. At Screening and on Day -1, if the triplicate 12-lead ECG demonstrates any of the following: mean PR >250ms; QRS >110 ms, or QTcF >560 ms and \<480 ms; bundle branch block or significant ST-T wave abnormalities or flat T waves that could interfere with QT analysis. Heart rate \<45 bpm, unless receiving a beta-blocker in which case \<40 bpm, or HR >95 bpm. If any of these exclusionary criteria are met, then a second set of triplicate ECGs may be acquired, and the mean values may be used. For participants on beta blockade, the PR interval may be higher than 250 ms with sponsor and investigator approval.
  10. Atrial pacing rate set to ≥80 bpm in those with atrial pacing.
  11. Participant has a pacemaker or ICD that is actively used for ventricular pacing.
  12. Known sensitivity to kinase inhibitors or clinically significant drug allergies to any of the components of LQT-1213.
  13. Abnormal renal function with an eGFR of \<60 mL/min/1.73 m2, with eGFR calculated by the CKD-EPI formula at Screening. One retest of the exclusionary eGFR value is allowed at Screening and Check-in at the discretion of the investigator.
  14. Participant has abnormal liver function tests (transaminases greater than 2 × the upper limit of normal [ULN] or total bilirubin > 1.5 × ULN. If the participant has documented Gilbert's Syndrome, participation is at the combined principal investigator and Sponsor's discretion after review of historical liver and bilirubin tests.
  15. Participant has a positive serology test for HIV antibodies, hepatitis B surface antigen, or hepatitis C virus antibody at Screening.
  16. Participant has a hemoglobin \<11.0 g/dL, potassium \<3.8 mg/dL, magnesium \<1.8 mg/dL, or calcium \<8.5 mg/dL at Screening or baseline. One retest of exclusionary hemoglobin, potassium, magnesium, and calcium is allowed at the discretion of the investigator.
  17. Participant has a history of hypersensitivity to drugs with a clinically significant reaction or any clinically significant hypersensitivities.
  18. Participant has a clinically significant allergy to band aids, adhesive dressing, ECG electrodes, or medical tape.
  19. Participant has abnormal creatine phosphokinase test greater than 3 × the ULN at Screening or baseline. One retest of exclusionary abnormal creatine phosphokinase tests is allowed at the discretion of the investigator.
  20. Participant is currently taking, within the last 7 days before Spaulding admission or 5 half-lives (whichever is longer), or anticipates the use of any antiarrhythmic medications (including mexilitene except beta-blockers which are allowed,) or drugs known to affect the QT interval (including ranolazine; refer to drug lists for "Drugs with known, possible, or conditional risk of TdP" that are known to prolong the QT interval at https://crediblemeds.org), unless approved by the sponsor and principal investigator.
  21. Participant is not permitted to use/consume the following:

    1. Any drugs known to be significant strong inducers of CYP 3A enzymes, including St. John's Wort, for 28 days before Day -1 or 5 half-lives (whichever is longer) and through the Follow-up Visit.
    2. Seville oranges, grapefruit and/or grapefruit juice within 7 days before Check-in and is unwilling to abstain from consuming these items until the end of the study.
  22. Participant is considering or scheduled to undergo any surgical procedure during the study.
  23. Participant has experienced an acute illness that has resolved in less than 14 days before the first study drug dose or has had a major illness or hospitalization within 1 month before the first study drug dose.
  24. Participant is unwilling to abstain from ingestion of caffeine- or xanthine-containing products (eg, tea, coffee, chocolate, cola, etc.) beginning 96 hours before Check-in until the final PK sample of the study has been collected.
  25. Participant is unwilling to abstain from alcohol beginning 48 hours before Check-in and until the final PK sample of the study has been collected.
  26. Participant has a history of high alcohol consumption or substance abuse that would pose a risk for the participant's safety and compliance with the study protocol. Participant must not have positive screen for drugs of abuse at Screening or baseline and alcohol at baseline, except with sponsor permission. Participants may undergo a repeat urine drug screen at the discretion of the investigator.
  27. Participant, who, for any reason, is deemed by the investigator to be inappropriate for this study or has any condition which would confound or interfere with the evaluation of the safety, tolerability, or PK of the investigational drug or prevent compliance with the study protocol.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Part 1: Arm A: Dofetilide with dose-escalating LQT-1213 TID followed by Dofetilide with placebo

    Sequence A :Dofetilide 500 μg BID (Days 1-8) and LQT-1213 TID 0.25 mg/kg (Days 3 and 4), 0.50 mg/kg (Days 5 and 6), and 0.70 mg/kg on Days 7 and 8. After adequate washout, Dofetilide 500 μg BID (Days 1-8) and placebo (Days 3-8).

    Drug: LQT-1213 · Drug: Placebo · Drug: Dofetilide 250 μg Cap

  • Experimental
    Part 1: Arm B: Dofetilide with placebo followed by Dofetilide with LQT-1213 TID

    Sequence B : Dofetilide 500 μg BID, orally (Days 1-8) and placebo TID (Days 3-8). After adequate washout, Dofetilide 500 μg BID, orally (Days 1-8) and LQT-1213 3 times a day (TID) 0.25 mg/kg (Days 3 and 4), 0.50 mg/kg (Days 5 and 6), and 0.70 mg/kg on Days 7 and 8.

    Drug: LQT-1213 · Drug: Placebo · Drug: Dofetilide 250 μg Cap

  • Experimental
    Part 2: TID dosing of LQT-1213 16 mg (48 mg Daily)

    LQT-1213 16 mg TID (at time 0, 8 and 16 hours) on Days 2-4, with a final single morning dose on Day 4. Day 1 was placebo.

    Drug: LQT-1213 · Drug: Placebo

  • Experimental
    Part 2: TID dosing of LQT-1213 7mg (21 mg Daily)

    LQT-1213 7 mg TID (at time 0, 8 and 16 hours) on Days 2-4, with a final single morning dose on Day 4. Day 1 was placebo.

    Drug: LQT-1213 · Drug: Placebo

Interventions

  • DrugLQT-1213

    LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

  • DrugPlacebo

    Matching Placebo

  • DrugDofetilideStudies of DofetilideDofetilide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dofetilide is a potent, pure inward-rectifier potassium channels (IKr) blocker

06

What researchers measure

Primary outcomes

  1. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 2.0 hours after administration of study treatment on Day 4.

  2. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 2.5 hours after administration of study treatment on Day 4

  3. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 3.0 hours after administration of study treatment on Day 4

  4. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 3.5 hours after administration of study treatment on Day 4

  5. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 4.0 hours after administration of study treatment on Day 4

  6. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 2.0 hours after administration of study treatment on Day 6

  7. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 2.5 hours after administration of study treatment on Day 6

  8. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 3.0 hours after administration of study treatment on Day 6

  9. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 3.5 hours after administration of study treatment on Day 6

  10. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 4.0 hours after administration of study treatment on Day 6

  11. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 2.0 hours after administration of study treatment on Day 8

  12. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 2.5 hours after administration of study treatment on Day 8

  13. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 3.0 hours after administration of study treatment on Day 8

  14. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 3.5 hours after administration of study treatment on Day 8

  15. Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

    The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

    Time frame: 4.0 hours after administration of study treatment on Day 8

  16. Part 2: Safety and Tolerability of Oral LQT-1213 in Participants With LQT-2 or LQT-3

    The primary outcome is to measure the incidence of treatment emergent adverse events (TEAEs).

    Time frame: up to day 12

Secondary outcomes

  1. Part 1: Pharmacokinetic LQT-1213 AUC0-t

    Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration

    Time frame: 0 to 24 hours post-dose on Day 8

  2. Part 1: Pharmacokinetic Dofetilide AUC0-t

    Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration

    Time frame: 0 to 24 hours post-dose on Day 8

  3. Part 1: Pharmacokinetic LQT-1213 AUCtau

    AUCtau = Area under the curve from time 0 to 8.0 hours

    Time frame: Day 4,6, 8

  4. Part 1: Pharmacokinetic Dofetilide AUCtau

    AUCtau = Area under the curve from time 0 to 12 hours

    Time frame: Day 4,6,8

  5. Part 1: Pharmacokinetic LQT-1213 Cmax

    Maximum observed plasma drug concentration

    Time frame: Day 4,6,8

  6. Part 1: Pharmacokinetic Dofetilide Cmax

    Maximum observed plasma drug concentration

    Time frame: Day 4,6, 8

  7. Part 1: Pharmacokinetic LQT-1213 Tmax

    Time to the maximum observed plasma concentration

    Time frame: Day 4,6,8

  8. Part 1: Pharmacokinetic Dofetilide Tmax

    Time to the maximum observed plasma concentration

    Time frame: Day 4,6,8

  9. Part 1: Pharmacokinetic LQT-1213 t1/2

    Terminal half-life

    Time frame: Day 8

  10. Part 1: Pharmacokinetic Dofetilide t1/2

    Terminal half-life

    Time frame: Day 8

  11. Part 1: Number of Treatment Emerging Adverse Events (TEAEs)

    Part 1: Number of Treatment Emerging Adverse Events (TEAEs) that occurred following administration of dofetilide Day1 up to Day 10 period 1 and in period 2 from Day 1 to up to the follow-up visit at Day 17.

    Time frame: Period 1 from Day 1 to Day 10 and Period 2 from Day 1 up to Day 17.

  12. Part 2: Pharmacokinetic LQT-1213 AUC0-t

    Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration

    Time frame: Day 4 Pre-dose up to 29 hours post-dose administration

  13. Part 2: Pharmacokinetic LQT-1213 AUCtau

    Pharmacokinetic LQT-1213 AUCtau (time 0 to 8 hours)

    Time frame: day 2 and day 4

  14. Part 2: Pharmacokinetic LQT-1213 Cmax

    Maximum observed plasma drug concentration

    Time frame: day 2 and day 4

  15. Part 2: Pharmacokinetic LQT-1213 Tmax

    Time to the maximum observed plasma concentration

    Time frame: Day 2 and Day 4

  16. Part 2: Pharmacokinetic LQT-1213 t1/2

    Part 2: Pharmacokinetic LQT-1213 terminal half-life t1/2

    Time frame: Day 4

Other outcomes

  1. Part 2: Time-matched Placebo-corrected QTcF - 1 Hour Post Dose

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 1 hour after administration of study treatment on Day 4.

  2. Part 2: Time-matched Placebo-corrected QTcF at 2 Hours Post-dose

    QTcF values at each timepoint on Day 4 were compared to the time-matched QTcF value on Day 1 (placebo) using the paired t-test.

    Time frame: 2 hours after administration of study treatment on Day 4.

  3. Part 2: Time-matched Placebo-corrected QTcF at 3 Hours Post-dose

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 3 hours after administration of study treatment on Day 4.

  4. Part 2: Time-matched Placebo-corrected QTcF at 4 Hours Post-dose

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 4 hours after administration of study treatment on Day 4.

  5. Part 2: Time-matched Placebo-corrected QTcF at 6 Hours Post-dose

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 6 hours after administration of study treatment on Day 4.

  6. Part 2: Time-matched Placebo-corrected QTcF at 8 Hours Post-dose

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 8 hours after administration of study treatment on Day 4.

  7. Part 2: Time-matched Placebo-corrected QTcF at 10 Hours Post-dose

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 10 hours after administration of study treatment on Day 4.

  8. Part 2: Time-matched Placebo-corrected QTcF at 12 Hours Post-dose

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 12 hours after administration of study treatment on Day 4.

  9. Part 2: Time-matched Placebo-corrected QTcF at 1 Hour Post-dose (Low Dose)

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 1 hours after administration of study treatment on Day 4.

  10. Part 2: Time-matched Placebo-corrected QTcF at 2 Hours Post-dose (Low Dose)

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 2 hours after administration of study treatment on Day 4.

  11. Part 2: Time-matched Placebo-corrected QTcF at 3 Hours Post-dose (Low Dose)

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test, which was the same as analyzing the difference of the time-matched QTcF values using one-sample t test.

    Time frame: 3 hours after administration of study treatment on Day 4.

  12. Part 2: Time-matched Placebo-corrected QTcF at 4 Hours Post-dose (Low Dose)

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 4 hours after administration of study treatment on Day 4.

  13. Part 2: Time-matched Placebo-corrected QTcF at 6 Hours Post-dose (Low Dose)

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 6 hours after administration of study treatment on Day 4.

  14. Part 2: Time-matched Placebo-corrected QTcF at 8 Hours Post-dose (Low Dose)

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 8 hours after administration of study treatment on Day 4.

  15. Part 2: Time-matched Placebo-corrected QTcF at 10 Hours Post-dose (Low Dose)

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 10 hours after administration of study treatment on Day 4.

  16. Part 2: Time-matched Placebo-corrected QTcF at 12 Hours Post-dose (Low Dose)

    QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

    Time frame: 12 hours after administration of study treatment on Day 4.

  17. Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)

    QTcF area under the curve on Day 4 (2 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (2 to 6 hours; placebo).

    Time frame: Day 4

  18. Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)

    QTcF area under the curve on Day 4 (3 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (3 to 6 hours; placebo).

    Time frame: Day 4

  19. Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)

    QTcF area under the curve on Day 4 (0 to 8 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 8 hours; placebo).

    Time frame: Day 4

  20. Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)

    QTcF area under the curve on Day 4 (0 to 12 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 12 hours; placebo).

    Time frame: Day 4

  21. Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)

    QTcF area under the curve on Day 4 (2 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (2 to 6 hours; placebo).

    Time frame: Day 4

  22. Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)

    QTcF area under the curve on Day 4 (3 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (3 to 6 hours; placebo).

    Time frame: Day 4

  23. Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)

    QTcF area under the curve on Day 4 (0 to 8 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 8 hours; placebo).

    Time frame: Day 4

  24. Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)

    QTcF area under the curve on Day 4 (0 to 12 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 12 hours; placebo).

    Time frame: Day 4

  25. Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)

    QTcF area under the curve on Day 4 (2 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (2 to 6 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms

    Time frame: Day 4

  26. Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)

    QTcF area under the curve on Day 4 (3 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (3 to 6 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms

    Time frame: Day 4

  27. Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)

    QTcF area under the curve on Day 4 (0 to 8 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 8 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms

    Time frame: Day 4

  28. Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)

    QTcF area under the curve on Day 4 (0 to 12 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 12 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms

    Time frame: Day 4

07

Results

Posted Jul 24, 2025

Participant flow

Participant flow — Overall Study
MilestonePart 1: Arm A: Dofetilide With Dose-escalating LQT-1213 TID Followed by Dofetilide With PlaceboPart 1: Arm B: Dofetilide With Placebo Followed by Dofetilide With LQT-1213 TIDPart 2: TID Dosing of LQT-1213 16 mg (48 mg Daily)Part 2: TID Dosing of LQT-1213 7 mg (21 mg Daily)
Started151566
Completed121166
Not completed3400
Withdrew: Withdrawal by subject1000
Withdrew: Physician decision2400

Outcome measures

PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
2.0 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.25 mg/kg (Day 4)Dofetilide + Placebo (Day 4)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo40.8 ± 11.0850.3 ± 14.77
Statistical analysis
  • Dofetilide + LQT-1213 0.25 mg/kg (Day 4) vs Dofetilide + Placebo (Day 4) · Mixed Models Analysis · p = 0.0030 · Ls mean: -9.6
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
2.5 hours after administration of study treatment on Day 4
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.25 mg/kg (Day 4)Dofetilide + Placebo (Day 4)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo43.3 ± 11.7648.0 ± 11.42
Statistical analysis
  • Dofetilide + LQT-1213 0.25 mg/kg (Day 4) vs Dofetilide + Placebo (Day 4) · Mixed Models Analysis · p = 0.0266 · Ls mean: -6.5
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
3.0 hours after administration of study treatment on Day 4
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.25 mg/kg (Day 4)Dofetilide + Placebo (Day 4)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo40.9 ± 11.0548.6 ± 12.93
Statistical analysis
  • Dofetilide + LQT-1213 0.25 mg/kg (Day 4) vs Dofetilide + Placebo (Day 4) · Mixed Models Analysis · p = 0.0067 · Ls mean: -7.8
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
3.5 hours after administration of study treatment on Day 4
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.25 mg/kg (Day 4)Dofetilide + Placebo (Day 4)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo43.4 ± 13.0146.4 ± 11.33
Statistical analysis
  • Dofetilide + LQT-1213 0.25 mg/kg (Day 4) vs Dofetilide + Placebo (Day 4) · Mixed Models Analysis · p = 0.1106 · Ls mean: -3.9
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
4.0 hours after administration of study treatment on Day 4
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.25 mg/kg (Day 4)Dofetilide + Placebo (Day 4)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo39.2 ± 10.8543.3 ± 13.83
Statistical analysis
  • Dofetilide + LQT-1213 0.25 mg/kg (Day 4) vs Dofetilide + Placebo (Day 4) · Mixed Models Analysis · p = 0.0908 · Ls mean: -4.2
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
2.0 hours after administration of study treatment on Day 6
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.50 mg/kg (Day 6)Dofetilide + Placebo (Day 6)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo42.4 ± 15.8943.9 ± 16.41
Statistical analysis
  • Dofetilide + LQT-1213 0.50 mg/kg (Day 6) vs Dofetilide + Placebo (Day 6) · Mixed Models Analysis · p = 0.4038 · Ls mean: -1.2
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
2.5 hours after administration of study treatment on Day 6
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.50 mg/kg (Day 6)Dofetilide + Placebo (Day 6)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo43.7 ± 14.7442.5 ± 16.93
Statistical analysis
  • Dofetilide + LQT-1213 0.50 mg/kg (Day 6) vs Dofetilide + Placebo (Day 6) · Mixed Models Analysis · p = 0.6255 · Ls mean: 1.5
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
3.0 hours after administration of study treatment on Day 6
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.50 mg/kg (Day 6)Dofetilide + Placebo (Day6)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo42.3 ± 12.5740.4 ± 16.70
Statistical analysis
  • Dofetilide + LQT-1213 0.50 mg/kg (Day 6) vs Dofetilide + Placebo (Day6) · Mixed Models Analysis · p = 0.5140 · Ls mean: 0.2
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
3.5 hours after administration of study treatment on Day 6
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecLQT-1213 0.50 mg/kg (Day 6)Dofetilide + Placebo (Day 6)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo42.0 ± 13.4040.7 ± 15.45
Statistical analysis
  • LQT-1213 0.50 mg/kg (Day 6) vs Dofetilide + Placebo (Day 6) · Mixed Models Analysis · p = 0.5675 · Ls mean: 0.8
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
4.0 hours after administration of study treatment on Day 6
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.50 mg/kg (Day 6)Dofetilide + Placebo (Day 6)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo38.5 ± 14.6435.3 ± 17.14
Statistical analysis
  • Dofetilide + LQT-1213 0.50 mg/kg (Day 6) vs Dofetilide + Placebo (Day 6) · Mixed Models Analysis · p = 0.7640 · Ls mean: 3.4
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
2.0 hours after administration of study treatment on Day 8
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.70 mg/kg (Day 8)Dofetilide + Placebo (Day 8)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo45.0 ± 14.3148.9 ± 13.94
Statistical analysis
  • Dofetilide + LQT-1213 0.70 mg/kg (Day 8) vs Dofetilide + Placebo (Day 8) · Mixed Models Analysis · p = .2437 · Ls mean: -2.8
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
2.5 hours after administration of study treatment on Day 8
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecLQT-1213 0.70 mg/kg (Day 8)Dofetilide + Placebo (Day 8)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo46.6 ± 14.2346.8 ± 11.45
Statistical analysis
  • LQT-1213 0.70 mg/kg (Day 8) vs Dofetilide + Placebo (Day 8) · Mixed Models Analysis · p = 0.4229 · Ls mean: -0.8
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
3.0 hours after administration of study treatment on Day 8
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.70 mg/kg (Day 8)Dofetilide + Placebo (Day 8)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo46.4 ± 15.1848.0 ± 13.24
Statistical analysis
  • Dofetilide + LQT-1213 0.70 mg/kg (Day 8) vs Dofetilide + Placebo (Day 8) · Mixed Models Analysis · p = 0.4887 · Ls mean: -0.1
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
3.5 hours after administration of study treatment on Day 8
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.70 mg/kg (Day 8)Dofetilide + Placebo (Day 8)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo44.4 ± 13.8448.3 ± 12.34
Statistical analysis
  • Dofetilide + LQT-1213 0.70 mg/kg (Day 8) vs Dofetilide + Placebo (Day 8) · Mixed Models Analysis · p = 0.2042 · Ls mean: -3.1
PrimaryPart 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo

The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.

Time frame:
4.0 hours after administration of study treatment on Day 8
Reported as:
Mean · msec
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
msecDofetilide + LQT-1213 0.70 mg/kg (Day 8)Dofetilide + Placebo (Day 8)
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo41.4 ± 12.2545.7 ± 11.75
Statistical analysis
  • Dofetilide + LQT-1213 0.70 mg/kg (Day 8) vs Dofetilide + Placebo (Day 8) · Mixed Models Analysis · p = 0.2644 · Mean difference (net): -2.2
PrimaryPart 2: Safety and Tolerability of Oral LQT-1213 in Participants With LQT-2 or LQT-3

The primary outcome is to measure the incidence of treatment emergent adverse events (TEAEs).

Time frame:
up to day 12
Reported as:
Number · TEAE
Part 2: Safety and Tolerability of Oral LQT-1213 in Participants With LQT-2 or LQT-3
TEAELQT-1213 16 mg TID (48 mg Daily)LQT-1213 7mg Tid (21 mg Daily)Placebo in LQT-1213 16 mg TID (48 mg)Placebo in LQT-1213 7 mg TID (21 mg)
Part 2: Safety and Tolerability of Oral LQT-1213 in Participants With LQT-2 or LQT-34312
SecondaryPart 1: Pharmacokinetic LQT-1213 AUC0-t

Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration

Time frame:
0 to 24 hours post-dose on Day 8
Reported as:
Geometric mean · h*ng/ml
Part 1: Pharmacokinetic LQT-1213 AUC0-t
h*ng/mlLQT-1213 TID 0.70 mg/kg
Part 1: Pharmacokinetic LQT-1213 AUC0-t13221.182 ± 47.6
SecondaryPart 1: Pharmacokinetic Dofetilide AUC0-t

Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration

Time frame:
0 to 24 hours post-dose on Day 8
Reported as:
Geometric mean · h*ng/ml
Part 1: Pharmacokinetic Dofetilide AUC0-t
h*ng/mlDofetilide 500 μg + Placebo Day 8Dofetilide 500 μg + LQT-1213
Part 1: Pharmacokinetic Dofetilide AUC0-t50.160 ± 18.651.863 ± 17.1
SecondaryPart 1: Pharmacokinetic LQT-1213 AUCtau

AUCtau = Area under the curve from time 0 to 8.0 hours

Time frame:
Day 4,6, 8
Reported as:
Geometric mean · h*ng/ml
Part 1: Pharmacokinetic LQT-1213 AUCtau
h*ng/mlLQT-1213 0.25 mg/kg (Day 4) TIDLQT-1213 0.50 mg/kg (Day 6) TIDLQT-1213 0.70 mg/kg (Day 8) TID
Part 1: Pharmacokinetic LQT-1213 AUCtau2735.793 ± 47.95433.729 ± 49.68763.318 ± 48.0
SecondaryPart 1: Pharmacokinetic Dofetilide AUCtau

AUCtau = Area under the curve from time 0 to 12 hours

Time frame:
Day 4,6,8
Reported as:
Geometric mean · h*ng/ml
Part 1: Pharmacokinetic Dofetilide AUCtau
h*ng/mlDofetilide 500 μg + Placebo (Day 4)Dofetilide 500 μg + Placebo (Day 6)Dofetilide 500 μg +Placebo (Day 8)Dofetilide + LQT-1213 (Day 4)Dofetilide + LQT-1213 (Day 6)Dofetilide + LQT-1213 (Day 8)
Part 1: Pharmacokinetic Dofetilide AUCtau36.350 ± 17.335.916 ± 15.337.075 ± 16.035.142 ± 18.436.390 ± 16.638.227 ± 15.3
SecondaryPart 1: Pharmacokinetic LQT-1213 Cmax

Maximum observed plasma drug concentration

Time frame:
Day 4,6,8
Reported as:
Geometric least squares mean · ng/ml
Part 1: Pharmacokinetic LQT-1213 Cmax
ng/mlLQT-1213 0.25 mg/kg (Day 4) TIDLQT-1213 0.50 mg/kg (Day 6) TIDLQT-1213 0.70 mg/kg (Day 8) TID
Part 1: Pharmacokinetic LQT-1213 Cmax501.739 ± 48.01013.942 ± 52.11612.274 ± 48.5
SecondaryPart 1: Pharmacokinetic Dofetilide Cmax

Maximum observed plasma drug concentration

Time frame:
Day 4,6, 8
Reported as:
Geometric mean · ng/ml
Part 1: Pharmacokinetic Dofetilide Cmax
ng/mlDofetilide 500 μg (Day 4)Dofetilide 500 μg (Day 6)Dofetilide 500 μg (Day 8)Dofetilide + LQT-1213 (Day 4)Dofetilide + LQT-1213 (Day 6)Dofetilide + LQT-1213 (Day 8)
Part 1: Pharmacokinetic Dofetilide Cmax4.367 ± 18.74.394 ± 16.94.580 ± 16.84.184 ± 19.04.438 ± 19.64.727 ± 20.6
SecondaryPart 1: Pharmacokinetic LQT-1213 Tmax

Time to the maximum observed plasma concentration

Time frame:
Day 4,6,8
Reported as:
Median · hours
Part 1: Pharmacokinetic LQT-1213 Tmax
hoursLQT-1213 0.25 mg/kg (Day 4) TIDLQT-1213 0.50 mg/kg (Day 6) TIDLQT-1213 0.70 mg/kg (Day 8) TID
Part 1: Pharmacokinetic LQT-1213 Tmax1.012 (0.98 to 6.00)1.114 (0.98 to 5.06)1.999 (0.99 to 5.05)
SecondaryPart 1: Pharmacokinetic Dofetilide Tmax

Time to the maximum observed plasma concentration

Time frame:
Day 4,6,8
Reported as:
Median · hours
Part 1: Pharmacokinetic Dofetilide Tmax
hoursDofetilide 500 μg (Day 4)Dofetilide 500 μg (Day 6)Dofetilide 500 μg (Day 8)Dofetilide + LQT-1213 (Day 4)Dofetilide + LQT-1213 (Day 6)Dofetilide + LQT-1213 (Day 8)
Part 1: Pharmacokinetic Dofetilide Tmax2.012 (1.00 to 6.00)2.003 (1.00 to 3.52)2.017 (1.00 to 4.01)2.015 (1.00 to 451)2.008 (1.00 to 5.51)2.504 (1.01 to 4.02)
SecondaryPart 1: Pharmacokinetic LQT-1213 t1/2

Terminal half-life

Time frame:
Day 8
Reported as:
Geometric mean · hours
Part 1: Pharmacokinetic LQT-1213 t1/2
hoursLQT-1213 TID 0.70 mg/kg
Part 1: Pharmacokinetic LQT-1213 t1/28.374 ± 22.0
SecondaryPart 1: Pharmacokinetic Dofetilide t1/2

Terminal half-life

Time frame:
Day 8
Reported as:
Geometric mean · hours
Part 1: Pharmacokinetic Dofetilide t1/2
hoursDofetilide 500 μg + Placebo Day 8Dofetilide + LQT-1213 (Day 8)
Part 1: Pharmacokinetic Dofetilide t1/27.139 ± 16.27.341 ± 14.6
SecondaryPart 1: Number of Treatment Emerging Adverse Events (TEAEs)

Part 1: Number of Treatment Emerging Adverse Events (TEAEs) that occurred following administration of dofetilide Day1 up to Day 10 period 1 and in period 2 from Day 1 to up to the follow-up visit at Day 17.

Time frame:
Period 1 from Day 1 to Day 10 and Period 2 from Day 1 up to Day 17.
Reported as:
Number · TEAE
Part 1: Number of Treatment Emerging Adverse Events (TEAEs)
TEAEDofetilideDofetilide + Low Dose LQT-1213 TID 0.25 mg/kg (Days 3 and 4)Dofetilide + Mid Dose LQT-1213 TID 0.50 mg/kg (Days 5 and 6)Dofetilide + High Dose LQT-1213 TID 0.70 mg/kg (Days 7 and 8)Dofetilide + Placebo
Part 1: Number of Treatment Emerging Adverse Events (TEAEs)12612125
SecondaryPart 2: Pharmacokinetic LQT-1213 AUC0-t

Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration

Time frame:
Day 4 Pre-dose up to 29 hours post-dose administration
Reported as:
Geometric mean · h*ng/ml
Part 2: Pharmacokinetic LQT-1213 AUC0-t
h*ng/mlLQT-1213 16 mg TID (48 mg Daily)LQT-1213 7mg Tid (21 mg Daily)
Part 2: Pharmacokinetic LQT-1213 AUC0-t5968 ± 30.92109 ± 19.5
SecondaryPart 2: Pharmacokinetic LQT-1213 AUCtau

Pharmacokinetic LQT-1213 AUCtau (time 0 to 8 hours)

Time frame:
day 2 and day 4
Reported as:
Geometric mean · h*ng/ml
Part 2: Pharmacokinetic LQT-1213 AUCtau
h*ng/mlLQT-1213 16 mg TID (48 mg Daily)LQT-1213 7mg Tid (21 mg Daily)
Day 22214 ± 41.7635.3 ± 22.8
Day 43314 ± 32.31153 ± 28.0
SecondaryPart 2: Pharmacokinetic LQT-1213 Cmax

Maximum observed plasma drug concentration

Time frame:
day 2 and day 4
Reported as:
Geometric mean · ng/ml
Part 2: Pharmacokinetic LQT-1213 Cmax
ng/mlLQT-1213 16 mg TID (48 mg Daily)LQT-1213 7mg Tid (21 mg Daily)
Day 2470.9 ± 46.5116.4 ± 23.8
Day 4562.9 ± 44.4195.1 ± 33.9
SecondaryPart 2: Pharmacokinetic LQT-1213 Tmax

Time to the maximum observed plasma concentration

Time frame:
Day 2 and Day 4
Reported as:
Median · ng/ml
Part 2: Pharmacokinetic LQT-1213 Tmax
ng/mlLQT-1213 16 mg TID (48 mg Daily)LQT-1213 7mg Tid (21 mg Daily)
Day 21.523 (1.01 to 4.01)1.268 (1.00 to 2.01)
Day 41.534 (0.98 to 4.01)1.781 (1.02 to 5.00)
SecondaryPart 2: Pharmacokinetic LQT-1213 t1/2

Part 2: Pharmacokinetic LQT-1213 terminal half-life t1/2

Time frame:
Day 4
Reported as:
Geometric mean · hours
Part 2: Pharmacokinetic LQT-1213 t1/2
hoursLQT-1213 16 mg TID (48 mg Daily)LQT-1213 7mg Tid (21 mg Daily)
Part 2: Pharmacokinetic LQT-1213 t1/211.97 ± 11.89.982 ± 9.8
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF - 1 Hour Post Dose

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
1 hour after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF - 1 Hour Post Dose
msecLQT-1213 16 mg TID (48 mg Daily) Day 4Placebo TID (Day1)
Part 2: Time-matched Placebo-corrected QTcF - 1 Hour Post Dose519.17 ± 32.344514.89 ± 29.569
Statistical analysis
  • LQT-1213 16 mg TID (48 mg Daily) Day 4 vs Placebo TID (Day1) · t-test, 2 sided · p = 0.3169 · Mean difference (net): 4.28
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 2 Hours Post-dose

QTcF values at each timepoint on Day 4 were compared to the time-matched QTcF value on Day 1 (placebo) using the paired t-test.

Time frame:
2 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 2 Hours Post-dose
msecTID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)TID Dosing of Placebo (Day 1)
Part 2: Time-matched Placebo-corrected QTcF at 2 Hours Post-dose520.06 ± 31.231513.28 ± 23.733
Statistical analysis
  • TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) vs TID Dosing of Placebo (Day 1) · t-test, 2 sided · p = 0.1066 · Mean difference (net): 6.78
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 3 Hours Post-dose

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
3 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 3 Hours Post-dose
msecTID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)Placebo TID Dosing Day 1
Part 2: Time-matched Placebo-corrected QTcF at 3 Hours Post-dose513.94 ± 26.410530.00 ± 39.838
Statistical analysis
  • TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) vs Placebo TID Dosing Day 1 · t-test, 2 sided · p = 0.0443 · Mean difference (net): -16.06
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 4 Hours Post-dose

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
4 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 4 Hours Post-dose
msecTID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)TID Dosing of Placebo (Day 1)
Part 2: Time-matched Placebo-corrected QTcF at 4 Hours Post-dose514.61 ± 28.450523.67 ± 32.158
Statistical analysis
  • TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) vs TID Dosing of Placebo (Day 1) · t-test, 2 sided · p = 0.0815 · Mean difference (net): -9.06
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 6 Hours Post-dose

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
6 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 6 Hours Post-dose
msecTID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)TID Dosing of Placebo (Day 1)
Part 2: Time-matched Placebo-corrected QTcF at 6 Hours Post-dose520.89 ± 26.741531.56 ± 32.897
Statistical analysis
  • TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) vs TID Dosing of Placebo (Day 1) · t-test, 2 sided · p = 0.0137 · Mean difference (net): -10.67
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 8 Hours Post-dose

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
8 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 8 Hours Post-dose
msecTID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)TID Dosing Placebo (Day 1)
Part 2: Time-matched Placebo-corrected QTcF at 8 Hours Post-dose503.61 ± 22.106507.61 ± 23.640
Statistical analysis
  • TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) vs TID Dosing Placebo (Day 1) · t-test, 2 sided · p = 0.3539 · Mean difference (net): -4.00
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 10 Hours Post-dose

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
10 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 10 Hours Post-dose
msecTID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)TID Dosing Placebo (Day 1)
Part 2: Time-matched Placebo-corrected QTcF at 10 Hours Post-dose521.00 ± 9.78511.22 ± 22.872
Statistical analysis
  • TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) vs TID Dosing Placebo (Day 1) · t-test, 2 sided · p = 0.1377 · Mean difference (net): 9.78
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 12 Hours Post-dose

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
12 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 12 Hours Post-dose
msecTID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)TID Dosing Placebo (Day 1)
Part 2: Time-matched Placebo-corrected QTcF at 12 Hours Post-dose519.42 ± 26.753522.11 ± 23.167
Statistical analysis
  • TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) vs TID Dosing Placebo (Day 1) · t-test, 2 sided · p = 0.6184 · Mean difference (net): -2.69
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 1 Hour Post-dose (Low Dose)

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
1 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 1 Hour Post-dose (Low Dose)
msecTID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily)TID Dosing Placebo Day 1
Part 2: Time-matched Placebo-corrected QTcF at 1 Hour Post-dose (Low Dose)524.39 ± 29.611521.22 ± 33.791
Statistical analysis
  • TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) vs TID Dosing Placebo Day 1 · t-test, 2 sided · p = 0.6627 · Mean difference (net): 3.17
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 2 Hours Post-dose (Low Dose)

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
2 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 2 Hours Post-dose (Low Dose)
msecTID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily)TID Dosing Placebo Day 1
Part 2: Time-matched Placebo-corrected QTcF at 2 Hours Post-dose (Low Dose)531.72 ± 38.880525.94 ± 29.837
Statistical analysis
  • TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) vs TID Dosing Placebo Day 1 · t-test, 2 sided · p = 0.5276 · Mean difference (net): 5.78
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 3 Hours Post-dose (Low Dose)

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test, which was the same as analyzing the difference of the time-matched QTcF values using one-sample t test.

Time frame:
3 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 3 Hours Post-dose (Low Dose)
msecTID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily)TID Dosing Placebo Day 1
Part 2: Time-matched Placebo-corrected QTcF at 3 Hours Post-dose (Low Dose)538.22 ± 38.584523.06 ± 33.857
Statistical analysis
  • TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) vs TID Dosing Placebo Day 1 · t-test, 2 sided · p = 0.0399 · Mean difference (net): 15.17
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 4 Hours Post-dose (Low Dose)

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
4 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 4 Hours Post-dose (Low Dose)
msecTID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily)TID Dosing Placebo Day 1
Part 2: Time-matched Placebo-corrected QTcF at 4 Hours Post-dose (Low Dose)535.72 ± 34.812522.17 ± 35.036
Statistical analysis
  • TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) vs TID Dosing Placebo Day 1 · t-test, 2 sided · p = 0.0747 · Mean difference (net): 13.56
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 6 Hours Post-dose (Low Dose)

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
6 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 6 Hours Post-dose (Low Dose)
msecTID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily)TID Dosing Placebo Day 1
Part 2: Time-matched Placebo-corrected QTcF at 6 Hours Post-dose (Low Dose)530.67 ± 43.213530.17 ± 32.590
Statistical analysis
  • TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) · t-test, 2 sided · p = 0.9584
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 8 Hours Post-dose (Low Dose)

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
8 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 8 Hours Post-dose (Low Dose)
msecTID Dosing of LQT-1213 7 mg (21 mg Daily)TID Dosing Placebo Day 1
Part 2: Time-matched Placebo-corrected QTcF at 8 Hours Post-dose (Low Dose)522.67 ± 33.363516.94 ± 51.848
Statistical analysis
  • TID Dosing of LQT-1213 7 mg (21 mg Daily) vs TID Dosing Placebo Day 1 · t-test, 2 sided · p = 0.6531 · Mean difference (net): 5.72
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 10 Hours Post-dose (Low Dose)

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
10 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 10 Hours Post-dose (Low Dose)
msecTID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily)TID Dosing Placebo Day 1
Part 2: Time-matched Placebo-corrected QTcF at 10 Hours Post-dose (Low Dose)530.39 ± 40.667514.78 ± 38.749
Statistical analysis
  • TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) vs TID Dosing Placebo Day 1 · t-test, 2 sided · p = 0.0482 · Mean difference (net): 15.61
Other pre-specifiedPart 2: Time-matched Placebo-corrected QTcF at 12 Hours Post-dose (Low Dose)

QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.

Time frame:
12 hours after administration of study treatment on Day 4.
Reported as:
Mean · msec
Part 2: Time-matched Placebo-corrected QTcF at 12 Hours Post-dose (Low Dose)
msecTID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily)TID Dosing Placebo Day 1
Part 2: Time-matched Placebo-corrected QTcF at 12 Hours Post-dose (Low Dose)536.11 ± 44.465518.89 ± 39.724
Statistical analysis
  • TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) vs TID Dosing Placebo Day 1 · t-test, 2 sided · p = 0.0667 · Mean difference (net): 17.22
Other pre-specifiedPart 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)

QTcF area under the curve on Day 4 (2 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (2 to 6 hours; placebo).

Time frame:
Day 4
Reported as:
Mean · msec*hour
Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)
msec*hourTID Dosing of Placebo Day1TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)
Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)2103.69 ± 130.8722066.69 ± 113.850
Statistical analysis
  • TID Dosing of Placebo Day1 vs TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) · t-test, 2 sided · p = 0.0131 · Mean difference (net): -37.00
Other pre-specifiedPart 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)

QTcF area under the curve on Day 4 (3 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (3 to 6 hours; placebo).

Time frame:
Day 4
Reported as:
Mean · msec*hour
Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)
msec*hourTID Dosing of Placebo Day1TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)
Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)1582.06 ± 100.2131549.69 ± 85.553
Statistical analysis
  • TID Dosing of Placebo Day1 vs TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) · t-test, 2 sided · p = 0.0141 · Mean difference (net): -32.36
Other pre-specifiedPart 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)

QTcF area under the curve on Day 4 (0 to 8 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 8 hours; placebo).

Time frame:
Day 4
Reported as:
Mean · msec*hour
Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)
msec*hourTID Dosing of Placebo Day1TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)
Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)4173.19 ± 236.7874128.64 ± 224.746
Statistical analysis
  • TID Dosing of Placebo Day1 vs TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) · t-test, 2 sided · p = 0.0019 · Mean difference (net): -44.55
Other pre-specifiedPart 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)

QTcF area under the curve on Day 4 (0 to 12 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 12 hours; placebo).

Time frame:
Day 4
Reported as:
Mean · msec*hour
Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)
msec*hourTID Dosing of Placebo Day1TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)
Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)6225.35 ± 323.6516193.67 ± 314.325
Statistical analysis
  • TID Dosing of Placebo Day1 vs TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) · t-test, 2 sided · p = 0.1108 · Mean difference (net): -31.69
Other pre-specifiedPart 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)

QTcF area under the curve on Day 4 (2 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (2 to 6 hours; placebo).

Time frame:
Day 4
Reported as:
Mean · msec*hour
Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)
msec*hourTID Dosing of Placebo Day1TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily)
Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)2099.44 ± 132.5662137.25 ± 150.766
Statistical analysis
  • TID Dosing of Placebo Day1 vs TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) · t-test, 2 sided · p = 0.1840 · Mean difference (net): 37.81
Other pre-specifiedPart 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)

QTcF area under the curve on Day 4 (3 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (3 to 6 hours; placebo).

Time frame:
Day 4
Reported as:
Mean · msec*hour
Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)
msec*hourTID Dosing of Placebo Day1TID Dosing of LQT-1213 7 mg (21 mg Daily)
Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)1574.94 ± 101.5831602.28 ± 112.284
Statistical analysis
  • TID Dosing of Placebo Day1 vs TID Dosing of LQT-1213 7 mg (21 mg Daily) · t-test, 2 sided · p = 0.2019 · Mean difference (net): 27.33
Other pre-specifiedPart 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)

QTcF area under the curve on Day 4 (0 to 8 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 8 hours; placebo).

Time frame:
Day 4
Reported as:
Mean · msec*hour
Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)
msec*hourTID Dosing of Placebo Day1TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily)
Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)4192.47 ± 279.3044248.69 ± 290.144
Statistical analysis
  • TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) · t-test, 2 sided · p = 0.2808
Other pre-specifiedPart 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)

QTcF area under the curve on Day 4 (0 to 12 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 12 hours; placebo).

Time frame:
Day 4
Reported as:
Mean · msec*hour
Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)
msec*hourTID Dosing of Placebo Day1TID Dosing of LQT-1213 7 mg (21 mg Daily)
Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)6257.86 ± 445.6996368.25 ± 444.031
Statistical analysis
  • TID Dosing of Placebo Day1 vs TID Dosing of LQT-1213 7 mg (21 mg Daily) · t-test, 2 sided · p = 0.1644 · Mean difference (net): 110.39
Other pre-specifiedPart 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)

QTcF area under the curve on Day 4 (2 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (2 to 6 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms

Time frame:
Day 4
Reported as:
Mean · msec*hour
Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)
msec*hourTID Dosing of Placebo Day1TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)
Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)2175.83 ± 85.5322131.54 ± 69.025
Statistical analysis
  • TID Dosing of Placebo Day1 vs TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) · t-test, 2 sided · p = 0.0282 · Mean difference (net): -44.29
Other pre-specifiedPart 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)

QTcF area under the curve on Day 4 (3 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (3 to 6 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms

Time frame:
Day 4
Reported as:
Mean · msec*hour
Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)
msec*hourTID Dosing of Placebo Day1TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)
Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)1636.33 ± 68.0131598.46 ± 51.804
Statistical analysis
  • TID Dosing of Placebo Day1 vs TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) · t-test, 2 sided · p = 0.0306 · Mean difference (net): -37.87
Other pre-specifiedPart 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)

QTcF area under the curve on Day 4 (0 to 8 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 8 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms

Time frame:
Day 4
Reported as:
Mean · msec*hour
Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)
msec*hourTID Dosing of Placebo Day1TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)
Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)4308.79 ± 135.6274255.38 ± 138.707
Statistical analysis
  • TID Dosing of Placebo Day1 vs TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) · t-test, 2 sided · p = 0.0016 · Mean difference (net): -53.42
Other pre-specifiedPart 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)

QTcF area under the curve on Day 4 (0 to 12 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 12 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms

Time frame:
Day 4
Reported as:
Mean · msec*hour
Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)
msec*hourTID Dosing of Placebo Day1TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily)
Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)6413.29 ± 175.1896369.04 ± 200.818
Statistical analysis
  • TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) · t-test, 2 sided · p = 0.1378 · Mean difference (net): -44.25

Adverse events

Collected over Part 1 : Period 1 (Day 1 to Day 10) and Period 2 (Day 1 to Day 17). Part 2: 12 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dofetilide0/30 (0%)0/30 (0%)0/30 (0%)
Dofetilide + Low Dose LQT-1213 TID 0.25 mg/kg (Days 3 and 4)0/29 (0%)0/29 (0%)0/29 (0%)
Dofetilide + Mid Dose LQT-1213 TID 0.50 mg/kg (Days 5 and 6)0/29 (0%)0/29 (0%)2/29 (6.9%)
Dofetilide + High Dose LQT-1213 0.70 mg/kg on (Days 7 and 8)0/25 (0%)0/25 (0%)0/25 (0%)
Dofetilide + Placebo0/25 (0%)0/29 (0%)4/29 (13.8%)
LQT-1213 16 mg TID0/6 (0%)0/6 (0%)3/6 (50%)
LQT-1213 7 mg TID0/6 (0%)0/6 (0%)1/6 (16.7%)
Placebo Matching LQT-1213 16 mg TID0/6 (0%)0/6 (0%)1/6 (16.7%)
Placebo Matching LQT-1213 7 mg TID0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Most frequent other events
EventDofetilideDofetilide + Low Dose LQT-1213 TID 0.25 mg/kg (Days 3 and 4)Dofetilide + Mid Dose LQT-1213 TID 0.50 mg/kg (Days 5 and 6)Dofetilide + High Dose LQT-1213 0.70 mg/kg on (Days 7 and 8)Dofetilide + PlaceboLQT-1213 16 mg TIDLQT-1213 7 mg TIDPlacebo Matching LQT-1213 16 mg TIDPlacebo Matching LQT-1213 7 mg TID
ErythemaSkin and subcutaneous tissue disorders0/300/290/290/250/292/61/60/60/6
PollakiuriaRenal and urinary disorders0/300/290/290/252/290/60/60/61/6
Skin tightnessSkin and subcutaneous tissue disorders0/300/290/290/250/290/61/60/61/6
Skin warmSkin and subcutaneous tissue disorders0/300/290/290/250/290/61/60/60/6
Pain in extremityMusculoskeletal and connective tissue disorders0/300/290/290/250/291/60/60/60/6
Rhinitis atrophicRespiratory, thoracic and mediastinal disorders0/300/290/290/250/291/60/60/60/6
Electrode site irritationSkin and subcutaneous tissue disorders0/300/290/290/250/290/60/61/60/6
Vessel puncture site painGeneral disorders0/300/292/290/254/290/60/60/60/6
Dry skinSkin and subcutaneous tissue disorders0/300/290/290/252/290/60/60/60/6
PalpitationsCardiac disorders0/300/290/290/252/290/60/60/60/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: Arm A: Dofetilide With Dose-escalating LQT-1213 TID Followed by Dofetilide With PlaceboPart 1: Arm B: Dofetilide With Placebo Followed by Dofetilide With LQT-1213 TIDPart 2: TID Dosing of LQT-1213 16 mgPart 2: TID Dosing of LQT-1213 7mgTotal
Mean43.3 ± 12.442.2 ± 9.1342.0 ± 13.7140.3 ± 8.3342 ± 10.84
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Arm A: Dofetilide With Dose-escalating LQT-1213 TID Followed by Dofetilide With PlaceboPart 1: Arm B: Dofetilide With Placebo Followed by Dofetilide With LQT-1213 TIDPart 2: TID Dosing of LQT-1213 16 mgPart 2: TID Dosing of LQT-1213 7mgTotal
Female544518
Male10112124
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Arm A: Dofetilide With Dose-escalating LQT-1213 TID Followed by Dofetilide With PlaceboPart 1: Arm B: Dofetilide With Placebo Followed by Dofetilide With LQT-1213 TIDPart 2: TID Dosing of LQT-1213 16 mgPart 2: TID Dosing of LQT-1213 7mgTotal
American Indian or Alaska Native00000
Asian12003
Native Hawaiian or Other Pacific Islander00000
Black or African American860014
White676625
More than one race00000
Unknown or Not Reported00000
body mass index
body mass index(kg/m2)Part 1: Arm A: Dofetilide With Dose-escalating LQT-1213 TID Followed by Dofetilide With PlaceboPart 1: Arm B: Dofetilide With Placebo Followed by Dofetilide With LQT-1213 TIDPart 2: TID Dosing of LQT-1213 16 mgPart 2: TID Dosing of LQT-1213 7mgTotal
Mean27.35 ± 3.36526.99 ± 2.94230.82 ± 6.97133.33 ± 7.56028.57 ± 4.33
08

Study locations

1 site
  • Spaulding Clinical Research, LLC
    West Bend, Wisconsin 53095, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in May 2024, 14 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2023
First posted
Jun 18, 2023
StartActual
Mar 12, 2023
Primary completionActual
May 31, 2024
CompletionActual
May 31, 2024
Results first posted
Jul 24, 2025
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05906732
Lead sponsor
Thryv Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Mar 12, 2023
Primary completion
May 31, 2024
Completion
May 31, 2024
Results posted
Jul 24, 2025
Last update
Jul 24, 2025

Study contacts

Jan Matousek, DO
principal investigator · Spaulding Clinical Research LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion